Chimeric Therapeutics
February 26, 2024
Oncology
Chimeric Therapeutics, is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer.
Chimeric is developing two first in class autologous CAR T cell therapies and a potentially best in class allogeneic NK cell therapy platform.
Chimeric assets are being investigated across multiple different disease areas in oncology including Colorectal Cancer, Gastric Cancer, Neuroendocrine Tumors, Acute Myeloid Leukemia and Glioblastoma.
Chimeric has presented positive preliminary data for two of their platforms, CHM 1101, a CLTX CAR T cell therapy in recurrent Glioblastoma and CHM 0201, an NK cell therapy platform in Acute Myeloid Leukemia.
Chimeric has 3 ongoing Phase 1B clinical programs and plans to open an additional Phase 1A clinical program in 2024.
Chimeric is currently listed on the ASX, with full operations in the United States.
)
){kind=logo}
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}